Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department

被引:9
|
作者
Garcia de Guadiana-Romualdo, Luis [1 ]
Cerezuela-Fuentes, Pablo [2 ]
Espanol-Morales, Ignacio [3 ]
Esteban-Torrella, Patricia [1 ]
Jimenez-Santos, Enrique [1 ]
Hernando-Holgado, Ana [1 ]
Dolores Albaladejo-Oton, Maria [1 ]
机构
[1] Univ Hosp Santa Lucia, Biochem Dept, Cartagena, Spain
[2] Univ Hosp Santa Lucia, Clin Oncol Dept, Cartagena, Spain
[3] Univ Hosp Santa Lucia, Hematol Dept, Cartagena, Spain
关键词
febrile neutropenia; prognosis; Multinational Association for Supportive Care in Cancer; procalcitonin; lipopolysaccharide binding protein; C-REACTIVE PROTEIN; RISK-INDEX SCORE; MULTINATIONAL-ASSOCIATION; DIAGNOSTIC-ACCURACY; SUPPORTIVE-CARE; BACTEREMIA; SEPSIS; INTERLEUKIN-6; MANAGEMENT; INFECTION;
D O I
10.11613/BM.2019.010702
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Introduction: Cancer patients with chemotherapy-induced febrile neutropenia are a heterogeneous group with a significant risk of serious medical complications. In these patients, the Multinational Association for Supportive Care in Cancer (MASCC) score is the most widely used tool for risk-stratification. The aim of this prospective study was to analyse the value of procalcitonin (PCT) and lipopolysaccharide binding protein (LBP) to predict serious complications and bacteraemia in cancer patients with febrile neutropenia, compared with MASCC score. Materials and methods: Data were collected from 111 episodes of febrile neutropenia admitted consecutively to the emergency department. In all of them, MASCC score was calculated and serum samples were collected for measurement of PCT and LBP by well-established methods. The main and secondary outcomes were the development of serious complications and bacteraemia, respectively. Results: A serious complication occurred in 20 (18%) episodes and in 16 (14%) bacteraemia was detected. Areas under the receiver operating characteristic curve (ROC AUC) of MASCC score, PCT and LBP to select low-risk patients were 0.83 (95% confidence interval (CI): 0.74 - 0.89), 0.85 (95% CI: 0.77 - 0.91) and 0.70 (95% CI: 0.61 - 0.78), respectively. For bacteraemia, MASCC score, PCT and LBP showed ROC AUCs of 0.74 (95% CI: 0.64 - 0.82), 0.86 (95% CI: 0.78 - 0.92) and 0.76 (95% CI: 0.67 - 0.83), respectively. Conclusion: A single measurement of PCT performs similarly as MASCC score to predict serious medical complications in cancer patients with febrile neutropenia and can be a useful tool for risk stratification. Besides, low PCT concentrations can be used to rule-out the presence of bacteraemia.
引用
收藏
页码:57 / 67
页数:11
相关论文
共 50 条
  • [21] The diagnostic and prognostic value of angiopoietins compared with C-reactive protein and procalcitonin in children with febrile neutropenia
    Mimaroglu, Esra
    Citak, Elvan Caglar
    Kuyucu, Necdet
    Eskendari, Gulcin
    [J]. TURKISH JOURNAL OF PEDIATRICS, 2017, 59 (04) : 418 - 425
  • [22] Emergency department waiting times for patients with cancer with febrile neutropenia: A pilot study
    Nirenberg, A
    Mulhearn, L
    Lin, S
    Larson, E
    [J]. ONCOLOGY NURSING FORUM, 2004, 31 (04) : 711 - 715
  • [23] Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department
    Choi, Arom
    Park, Incheol
    Lee, Hye Sun
    Chung, Jinseok
    Kim, Min Joung
    Park, Yoo Seok
    [J]. ANNALS OF MEDICINE, 2022, 54 (01) : 599 - 609
  • [24] Prognostic value of lipopolysaccharide binding protein and procalcitonin in patients with severe sepsis and septic shock admitted to intensive care
    Garcia de Guadiana-Romualdo, L. M.
    Rebotto-Acebes, S.
    Esteban-Torrella, P.
    Jimenez-Sanchez, R.
    Hernando-Holgado, A.
    Ortin-Freire, A.
    Viqueira-Gonzalez, M.
    Trujillo-Santos, J.
    Santos, E. Jimenez
    Pedregosa Diaz, J.
    Atbaladejo-Oton, M. D.
    Altegue-Gallego, J. M.
    [J]. MEDICINA INTENSIVA, 2015, 39 (04) : 207 - 212
  • [25] Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia
    Baugh, Christopher W.
    Faridi, Mohammad Kamal
    Mueller, Emily L.
    Camargo, Carlos A., Jr.
    Pallin, Daniel J.
    [J]. PLOS ONE, 2019, 14 (05):
  • [26] DIRECT COSTS ASSOCIATED WITH NEUTROPENIA AND FEBRILE NEUTROPENIA AS ADVERSE EVENTS OF CHEMOTHERAPY IN SERBIAN CANCER PATIENTS
    Lukic, S.
    Desnica, J.
    Stefanovic, K.
    Kostic, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S455 - S455
  • [27] OPTIMIZING A FEBRILE NEUTROPENIC CLINICAL PATHWAY FOR CANCER PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT
    Kempka, Kate
    Curtis, Tina
    Oxencis, Carolyn
    Charlson, John
    Mielnicki, Daniel
    Atkinson, Dave
    [J]. ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [28] Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients
    Heo, Sejin
    Jeon, Kyeongman
    Park, Boram
    Ko, Ryoung-Eun
    Kim, Taerim
    Hwang, Sung Yeon
    Yoon, Hee
    Shin, Tae Gun
    Cha, Won Chul
    Lee, Se Uk
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2023, 67 : 90 - 96
  • [29] Predictive value of peri-chemotherapy hematological parameters for febrile neutropenia in patients with cancer
    Jia, Hongyuan
    Liang, Long
    Chen, Xue
    Zha, Wenzhong
    Diao, Wei
    Zhang, Wei
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [30] Pharmacokinetics of Vancomycin among Patients with Chemotherapy-Associated Febrile Neutropenia: Which Would Be the Best Dosing to Obtain Appropriate Exposure?
    Parra Gonzalez, Daniel
    Perez Mesa, Jefferson Alejandro
    Cuervo Maldonado, Sonia Isabel
    Diaz Rojas, Jorge Augusto
    Alberto Cortes, Jorge
    Silva Gomez, Edelberto
    Saavedra Trujillo, Carlos Humberto
    Gomez, Julio
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (11):